Chimeric Antigen Receptors for Cancer Immunotherapy

  • Claudia Geldres
  • Barbara Savoldo
  • Gianpietro DottiEmail author
Part of the Methods in Molecular Biology book series (MIMB, volume 1393)


The adoptive transfer of T lymphocytes expressing chimeric antigen receptors (CARs) has emerged as a promising treatment for various lymphoid and solid malignancies. Patients treated with CAR-T cells have achieved dramatic responses and in some cases, complete tumor eradication. Given that CARs combine the specificity of a monoclonal antibody with the internal signaling domains of T cells, there is flexibility for choice of target antigen and strength of T-cell activation. This targeting mechanism also relinquishes the need for antigen processing and presentation via the major histocompatibility complex (MHC), making CARs a very attractive therapeutic option for the majority of patients. This review describes current methodological strategies used to generate CAR molecules, how to insert these molecules in T lymphocytes and how to evaluate the functionality of these CAR-T cells using various in vitro and in vivo experiments.

Key words

Immunotherapy Chimeric antigen receptor 



This work was supported in part by R01 CA142636 National Institutes of Health-NCI, W81XWH-10-10425 Department of Defence and Technology/Therapeutic Development Award.


  1. 1.
    Morgan RA, Dudley ME, Wunderlich JR et al (2006) Cancer regression in patients after transfer of genetically engineered lymphocytes. Science 314:126–129CrossRefPubMedPubMedCentralGoogle Scholar
  2. 2.
    Eshhar Z, Waks T, Gross G et al (1993) Specific activation and targeting of cytotoxic lymphocytes through chimeric single chains consisting of antibody-binding domains and the gamma or zeta subunits of the immunoglobulin and T-cell receptors. Proc Natl Acad Sci U S A 90:720–724CrossRefPubMedPubMedCentralGoogle Scholar
  3. 3.
    Louis CU, Savoldo B, Dotti G et al (2011) Antitumor activity and long-term fate of chimeric antigen receptor-positive T cells in patients with neuroblastoma. Blood 118:6050–6056CrossRefPubMedPubMedCentralGoogle Scholar
  4. 4.
    Pule MA, Savoldo B, Myers GD et al (2008) Virus-specific T cells engineered to coexpress tumor-specific receptors: persistence and antitumor activity in individuals with neuroblastoma. Nat Med 14:1264–1270CrossRefPubMedPubMedCentralGoogle Scholar
  5. 5.
    Jensen MC, Popplewell L, Cooper LJ et al (2010) Antitransgene rejection responses contribute to attenuated persistence of adoptively transferred CD20/CD19-specific chimeric antigen receptor redirected T cells in humans. Biol Blood Marrow Transplant 16:1245–1256CrossRefPubMedPubMedCentralGoogle Scholar
  6. 6.
    Park JR, Digiusto DL, Slovak M et al (2007) Adoptive transfer of chimeric antigen receptor re-directed cytolytic T lymphocyte clones in patients with neuroblastoma. Mol Ther 15:825–833CrossRefPubMedGoogle Scholar
  7. 7.
    Imai C, Mihara K, Andreansky M et al (2004) Chimeric receptors with 4-1BB signaling capacity provoke potent cytotoxicity against acute lymphoblastic leukemia. Leukemia 18:676–684CrossRefPubMedGoogle Scholar
  8. 8.
    Maher J, Brentjens RJ, Gunset G et al (2002) Human T-lymphocyte cytotoxicity and proliferation directed by a single chimeric TCRzeta/CD28 receptor. Nat Biotechnol 20:70–75Google Scholar
  9. 9.
    Ramos CA, Dotti G (2011) Chimeric antigen receptor (CAR)-engineered lymphocytes for cancer therapy. Expert Opin Biol Ther 11:855–873CrossRefPubMedPubMedCentralGoogle Scholar
  10. 10.
    Zhao Y, Wang QJ, Yang S et al (2009) A herceptin-based chimeric antigen receptor with modified signaling domains leads to enhanced survival of transduced T lymphocytes and antitumor activity. J Immunol 183:5563–5574CrossRefPubMedGoogle Scholar
  11. 11.
    Brentjens RJ, Davila ML, Riviere I et al (2013) CD19-targeted T cells rapidly induce molecular remissions in adults with chemotherapy-refractory acute lymphoblastic leukemia. Sci Transl Med 5:177ra138CrossRefGoogle Scholar
  12. 12.
    Kalos M, Levine BL, Porter DL et al (2011) T cells with chimeric antigen receptors have potent antitumor effects and can establish memory in patients with advanced leukemia. Sci Transl Med 3:95ra73CrossRefPubMedPubMedCentralGoogle Scholar
  13. 13.
    Savoldo B, Ramos CA, Liu E et al (2011) CD28 costimulation improves expansion and persistence of chimeric antigen receptor-modified T cells in lymphoma patients. J Clin Invest 121:1822–1826CrossRefPubMedPubMedCentralGoogle Scholar
  14. 14.
    Porter DL, Levine BL, Kalos M et al (2011) Chimeric antigen receptor-modified T cells in chronic lymphoid leukemia. N Engl J Med 365:725–733CrossRefPubMedPubMedCentralGoogle Scholar
  15. 15.
    Shu L, Qi CF, Schlom J et al (1993) Secretion of a single-gene-encoded immunoglobulin from myeloma cells. Proc Natl Acad Sci U S A 90:7995–7999CrossRefPubMedPubMedCentralGoogle Scholar
  16. 16.
    Vera J, Savoldo B, Vigouroux S et al (2006) T lymphocytes redirected against the kappa light chain of human immunoglobulin efficiently kill mature B lymphocyte-derived malignant cells. Blood 108:3890–3897CrossRefPubMedPubMedCentralGoogle Scholar

Copyright information

© Springer Science+Business Media New York 2016

Authors and Affiliations

  • Claudia Geldres
    • 1
    • 2
  • Barbara Savoldo
    • 1
    • 3
    • 4
  • Gianpietro Dotti
    • 1
    • 2
    • 4
    • 5
    • 6
    • 7
    • 8
    Email author
  1. 1.Center for Cell and Gene TherapyBaylor College of MedicineHoustonUSA
  2. 2.Interdepartmental Program in Translational Biology and Molecular MedicineBaylor College of MedicineHoustonUSA
  3. 3.Department of PediatricsBaylor College of MedicineHoustonUSA
  4. 4.Texas Children’s HospitalHoustonUSA
  5. 5.Departments of PathologyBaylor College of MedicineHoustonUSA
  6. 6.Departments of ImmunologyBaylor College of MedicineHoustonUSA
  7. 7.Department of MedicineBaylor College of MedicineHoustonUSA
  8. 8.Houston Methodist HospitalHoustonUSA

Personalised recommendations